Higher Blood THC Did Not Mean Greater Task Impairment Across User Groups

Frequent cannabis smokers had higher blood THC concentrations but weaker effects on some tasks than occasional smokers in a controlled-smoking study. The finding supports a limited, domain-specific role for tolerance; it does not show that frequent users were universally unimpaired.

One smoking session, different histories

Desrosiers and colleagues studied 14 frequent and 11 occasional smokers. Participants stayed on a secure research unit before smoking a cannabis cigarette containing approximately 54 mg THC, with smoking allowed to the participant’s desired comfort level within ten minutes.

The experiment measured blood cannabinoids, subjective effects and several performance domains. The groups were not randomized to develop different cannabis-use histories. They also differed in age and other history characteristics, and two participants were reclassified using their biological profiles.

Blood exposure and task responses diverged

At 30 minutes, mean blood THC was 32.3 ng/mL in frequent smokers and 17.4 ng/mL in occasional smokers. Nevertheless, occasional smokers generally showed stronger subjective effects and greater disruption of selected psychomotor and divided-attention measures.

The outcome was not uniform across the test battery. Working-memory and risk-taking tasks did not show the same session-by-group effects. The overall critical-tracking analysis was also not significant, although a specific contrast favored frequent smokers at 1.5 hours relative to their baselines. A broad claim that every cognitive function was impaired equally would misrepresent those results.

Tolerance is not a personal clearance certificate

There was no placebo smoking session. Consequently, changes over time may include fatigue, practice and boredom as well as drug effects. Some task data were excluded for poor baseline performance, and the small sample limited statistical power.

The study did not measure actual crash risk or identify an individual blood concentration at which driving became safe. Less impairment in one group is a relative comparison, not proof of normal performance in every frequent smoker.

In testimony or a report, name the affected task, comparison and user population instead of relying on the word “tolerant” alone. Our discussion of THC blood levels and impairment explains why concentration and functional evidence must be evaluated together.

Primary research

Nathalie A. Desrosiers and colleagues. Journal of Analytical Toxicology (2015). Smoked Cannabis’ Psychomotor and Neurocognitive Effects in Occasional and Frequent Smokers.

Spread the love


The National Black Lawyers

top 40 lawyers

civil trial law

Lawyers of Distinction

Loading...

Recent Blog Articles

A Higher Edible Dose Did Not Produce a Higher Mean Blood THC Peak in Every Group

A 50 mg edible THC dose did not produce a higher mean whole-blood THC peak than 25 mg in a small between-group study. That observation does not show reversed absorption or make blood concentration a reliable dose calculator. Only six people received each dose Healthy adults without recent cannabis use…

Spread the love

Read Article: A Higher Edible Dose Did Not Produce a Higher Mean Blood THC Peak in Every Group

Oral-Fluid Parent Cannabinoids and Metabolites Followed Different Route Patterns

An oral-fluid THC peak immediately after cannabis use can reflect material deposited in the mouth rather than peak systemic exposure. A controlled comparison of smoked, vaporized and edible cannabis found different route patterns for parent cannabinoids and metabolites. Within-person route comparisons Eleven frequent and nine occasional cannabis smokers completed a…

Spread the love

Read Article: Oral-Fluid Parent Cannabinoids and Metabolites Followed Different Route Patterns

Transdermal CBD’s Open-Label Seizure Improvement Did Not Reverse Its Blinded Null Result

Transdermal CBD did not significantly reduce seizure frequency compared with placebo during a blinded adult focal-epilepsy trial. Improvement during the later open-label extension answered a different question and did not overturn that randomized comparison. A daily-dose distinction clarified by correction The trial randomized 188 adults to transdermal CBD or placebo….

Spread the love

Read Article: Transdermal CBD’s Open-Label Seizure Improvement Did Not Reverse Its Blinded Null Result

Speak with an expert today!

Contact the offices of Okorie Okorocha for professional and reliable advice which you can trust.

Call (424) 363-3347 Contact Us